WallStSmart
MENS

Jyong Biotech Ltd. Ordinary Shares

NASDAQ: MENS · HEALTHCARE · BIOTECHNOLOGY

$2.07
-3.81% today

Updated 2026-06-05

Market cap
$120.12M
P/E ratio
P/S ratio
EPS (TTM)
$-0.06
Dividend yield
52W range
$1 – $67
Volume
0.1M

Jyong Biotech Ltd. Ordinary Shares (MENS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$121000.00$122000.00$127000.00$120000.00$100000.00
Gross profit$-121000.00$-122000.00$-127000.00$-120000.00$-100000.00
Gross margin
R&D$1.51M$1.56M$1.29M$1.07M$927000.00$731000.00
SG&A$859000.00$791000.00$1.49M$1.68M$1.08M$1.79M
Operating income$-2.45M$-2.40M$-2.83M$-2.80M$-2.06M$-2.61M
Operating margin
EBITDA$-2.34M$-3.24M$-5.74M$-3.52M$-1.86M$-2.51M
EBITDA margin
EBIT$-2.45M$-3.36M$-5.87M$-3.64M$-1.98M$-2.61M
Interest expense$832000.00$835000.00$765000.00$757000.00$1.03M$2.54M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.92M$-4.20M$-6.63M$-4.40M$-3.02M$-4.67M
Net income growth (YoY)-119.1%-57.9%+33.6%+31.4%-54.7%
Profit margin

Frequently asked questions

How much free cash flow does MENS generate?

MENS produced $-3.04M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MENS's balance sheet healthy?

MENS holds $1.18M in cash and equivalents against $10.16M in long-term debt, on $-24.91M of shareholder equity. That debt is best read against the cash flow the business throws off each year.